Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Chelation Warnings Reflect Growth In Bogus OTCs, Supplements

This article was originally published in The Tan Sheet

Executive Summary

FDA says its Oct. 14 warnings about unapproved autism treatment claims for chelation products marketed as OTCs or dietary supplements reflect a growing problem of fraud in consumer health care product marketing

You may also be interested in...



Regulatory News In Brief

Peanut recalls spread to nutrition bars; Maxam missing supplement manufacturing specs; Amazing Herbs slip on GMPs; FDA finds hygiene errors in Creation’s Garden; Avon, Bioque cosmetics make drug claims; more Regulatory News In Brief.

Regulatory News In Brief

Peanut recalls spread to nutrition bars; Maxam missing supplement manufacturing specs; Amazing Herbs slip on GMPs; FDA finds hygiene errors in Creation’s Garden; Avon, Bioque cosmetics make drug claims; more Regulatory News In Brief.

In Brief

Consent decree follows claim warning

Related Content

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel